Corbus Pharmaceuticals (NASDAQ: CRBP) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Corbus Pharmaceuticals to related businesses based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

27.8% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 11.9% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Corbus Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corbus Pharmaceuticals $1.91 million -$19.99 million -11.51
Corbus Pharmaceuticals Competitors $284.28 million $34.29 million 133.63

Corbus Pharmaceuticals’ competitors have higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals’ competitors have a beta of 5.86, indicating that their average share price is 486% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Corbus Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corbus Pharmaceuticals 0 0 3 0 3.00
Corbus Pharmaceuticals Competitors 848 3199 11594 230 2.71

Corbus Pharmaceuticals currently has a consensus target price of $23.67, suggesting a potential upside of 226.44%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.86%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Corbus Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals -1,040.41% -96.02% -77.38%
Corbus Pharmaceuticals Competitors -5,302.63% -356.16% -38.98%

Summary

Corbus Pharmaceuticals competitors beat Corbus Pharmaceuticals on 7 of the 12 factors compared.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company’s product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.